Quincy Bioscience researches, develops and plans to market therapeutic compounds for the treatment of neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, stroke, Huntington’s disease, and Amyotrophic Lateral Sclerosis (ALS). New therapeutics will be based on the calcium-binding protein aequorin. Calcium-binding proteins are important in the protection of certain cellular populations and decrease over the course of aging or disease progression. In June 2004, the company applied for its first patent on the aequorin technology. Research and development work is conducted in university laboratories in addition to Quincy Bioscience's own facilities to fully develop the therapeutic applications of this technology.
Aequorin acts in a protective manner similar to proteins that are depleted in humans with these diseases of aging. The dietary supplement Prevagen™ has been developed based on Quincy Bioscience’s core technology and is slated for launch into national markets on September 1, 2007. Prevagen is marketed to assist in the Fight Against Aging. More information on the dietary supplement applications of Quincy Bioscience's technology can be found at www.prevagen.com.
Quincy Bioscience is focused on the discovery, development and commercialization of novel medicines to treat the diseases of aging. The company's therapeutic products focus on alleviating the consequences of impaired calcium homeostasis - the imbalance of calcium ions commonly thought to be related to neurodegenerative diseases such as Alzheimer's and Parkinson's. Quincy Bioscience is set apart by its cutting-edge applications of the calcium-binding protein aequorin...breaking new ground in the fight against age-related disease.